1415338-40-7

Upstream product

• 187235-08-1 (S)‐2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazin‐6‐ol 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 1415338-41-8 (4-{[(S)-6,7-dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-yloxy]methyl}phenyl)(1-tert-butyl-1H-tetrazol-5-yl)-N,N-dimethylmethanamine 
• 1415338-42-9 (4-{[(S)-6,7-dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-yloxy]methyl}phenyl)(1-tert-butyl-1H-tetrazol-5-yl)-N,N-diethylmethanamine 
• 1415338-43-0 (S)-6-{4-[(1-tert-butyl-1H-tetrazol-5-yl)(pyrrolidin-1-yl)methyl]benzyloxy}-6,7-dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazine 

Relevant academic research and scientific papers

Synthesis and antiplasmodial and antimycobacterial evaluation of new nitroimidazole and nitroimidazooxazine derivatives

The synthesis and antiplasmodial and antimycobacterial evaluation of two new series of nitroimidazole and nitroimidazooxazine derivatives is described. The majority of these compounds, especially hybrids 9d, 9f, and 14b, exhibited potent activity against the chloroquine-resistant K1 strain of Plasmodium falciparum. Furthermore, a notable number from the tetrazole series were significantly more active against M. tuberculosis than kanamycin, a standard TB drug.